FY2024 EPS Estimates for Humacyte Lowered by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Humacyte in a report issued on Wednesday, November 13th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings per share of ($1.36) for the year, down from their previous estimate of ($1.28). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Humacyte’s FY2025 earnings at ($0.77) EPS.

A number of other research firms have also issued reports on HUMA. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 target price on Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. TD Cowen reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Humacyte has an average rating of “Buy” and an average target price of $11.00.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $4.84 on Friday. Humacyte has a 52 week low of $2.35 and a 52 week high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 1.10. The company has a market cap of $577.06 million, a PE ratio of -3.61 and a beta of 1.47. The firm has a 50 day simple moving average of $5.42 and a 200 day simple moving average of $6.17.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. This represents a 5.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 in the last quarter. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently modified their holdings of the company. Endowment Wealth Management Inc. raised its position in Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after purchasing an additional 3,000 shares during the last quarter. nVerses Capital LLC bought a new position in Humacyte in the 2nd quarter valued at $28,000. Private Advisor Group LLC raised its position in shares of Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after acquiring an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Humacyte by 32.5% in the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after purchasing an additional 8,965 shares during the period. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.